[{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"ea7b0831-aa27-4710-8ad0-16bc4a75633a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067776","created_at":"2023-10-05T16:11:05.700Z","updated_at":"2024-07-02T16:35:34.583Z","phase":"Phase 1","brief_title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","source_id_and_acronym":"NCT06067776","lead_sponsor":"Jonathan Riess","biomarkers":" HER-2 • BRAF • ALK • MET • RET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation","tags":["HER-2 • BRAF • ALK • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-10-05"},{"id":"8411cc8f-a982-4f1c-a6ee-8d632174e0c9","acronym":"RMC-4630-02","url":"https://clinicaltrials.gov/study/NCT03989115","created_at":"2021-01-18T19:36:51.447Z","updated_at":"2024-07-02T16:35:44.769Z","phase":"Phase 1/2","brief_title":"Dose-Esc/Exp RMC4630 \u0026 Cobi in Relapsed/Refractory Solid Tumors \u0026 RMC4630\u0026 Osi in EGFR+ Locally Adv/Meta NSCLC","source_id_and_acronym":"NCT03989115 - RMC-4630-02","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" EGFR • KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification","tags":["EGFR • KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cotellic (cobimetinib) • vociprotafib (RMC-4630)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 02/08/2022","primary_completion_date":" 02/08/2022","study_txt":" Completion: 02/08/2022","study_completion_date":" 02/08/2022","last_update_posted":"2023-06-26"},{"id":"a6bd584d-e831-4a8e-b3a3-6c9a3a80fc5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634982","created_at":"2021-01-18T17:51:01.596Z","updated_at":"2024-07-02T16:36:04.616Z","phase":"Phase 1","brief_title":"Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT03634982","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-09-01"},{"id":"128616b3-9bfc-47c1-8a87-e405466318de","acronym":"","url":"https://clinicaltrials.gov/study/NCT01449058","created_at":"2021-01-18T06:00:49.971Z","updated_at":"2024-07-02T16:37:17.396Z","phase":"Phase 1","brief_title":"A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT01449058","lead_sponsor":"Array BioPharma","biomarkers":" KRAS • BRAF • PIK3CA • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • PIK3CA mutation • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • PIK3CA • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • PIK3CA mutation • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Mektovi (binimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 08/31/2016","primary_completion_date":" 08/31/2016","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2017-10-02"}]